Table 2.
ANP levels influenced by medical or surgical intervention sorted in order of increasing age.
| Intervention | Age | n | ANP before intervention (pg/mL) | ANP after intervention (pg/mL) | ANP in controls (pg/mL) | Statistical operator | Blood sampling procedure | References | |
|---|---|---|---|---|---|---|---|---|---|
| Catheterization | 8.5 ± 5.5 d | 6 | 243.0 ± 42.1 | 30 min: 243.6 ± 48.4* FU: 62.1 ± 12.7* |
mean ± SD | IVC during catheterization Plasma |
I | Zeevi et al. (23) | |
| None | 14 ± 11 d | 7 | 220.8 ± 16.2 | ||||||
| Catheterization | 6.8 ± 6.4 y | 22 | 125.2 ± 15.8 | 30 min: 75.6 ± 11.4* FU: 42.9 ± 5.0* |
|||||
| None | 6.8 ± 2.5 y | 9 | 24.6 ± 4.6 | ||||||
| Cardiopulmonary bypass | 4.8 (2.5–9.9) mo | 5 | 175.1 (115–437) | 1 day: 44 (28–81)* | n/a | median (range) | Arterial catheter Plasma |
I | Costello et al. (20) |
| Cardiac surgery | 41.11 ± 25.39 mo | 27 | Normal PBF: 175.9 ± 253.2 | 24 h: 149.3n.s. 48 h: 155.8n.s. |
mean ± SD | 15 min supine 9:00 am Before surgery: peripheral vein After surgery: central venous catheter Plasma |
I | Alvarez Kindelan et al. (26) |
|
| 30.61 ± 40.74 mo | 38 | High PBF: 229.9 ± 311.2 | 24 h: 183.8n.s. 48 h: 187.2n.s. |
||||||
| None | 0.2–14 y | 48 | 46.5 ± 25.5 | ||||||
| Catheterization | 3.1 (0.3–13) y | 59 | 99.8 ± 60.2 | 8 mo: 23.8 ± 10.1* | n/a | mean ± SD | During cardiac catheterization Femoral vein Plasma |
I | Suda et al. (11) |
| Right venricular angiography | 6.8 (1.8–14.7) y | 21 | TOF before: IVC: 68 (10–169) PA: 139 (10–262) AO: 133 (10–365) LA: 128 (24–210) RA: 114 (10–308) |
After: IVC: 217 (42–612)* PA: 33 (49–805)* AO: 360 (95–910)* LA: 228 (77–525)* RA: 298 (21–875)* |
mean (range) | Plasma | I | Oberhänsli et al. (22) | |
| 5.0 (0.6–13.1) y | 24 | LRS with pulmonary hypertension before: IVC: 198 (10–1417) PA: 456 (10–1697) AO: 336 (10 −1190) RA: 360 (10–1655) |
After: IVC: 412 (63–1568)* PA: 883 (74–3220)* AO: 760 (116–1960)* RA: 594 (45–2275)* |
||||||
| Right venricular angiography | 6.2 (1.3–16.4) y | 12 | Controls after: IVC: 181 (70–346)* PA: 207 (105–266)* AO: 221 (66–567)* RA: 260 (122–378)* |
Before: IVC: 56 (28–162) PA: 90 (46–147) AO: 78 (38–168) RA: 70 (35–122) |
|||||
| Transcatheter closure of ASD | 10.6 ± 3.6 y | 14 | 24 ± 9.8 | 5 min: 34 ± 18* 24 h: 19 ± 11n.s. |
mean ± SD | Supine Peripheral vein Plasma |
I | Muta et al. (24) | |
| None | 6–18 y | 10 | 17 ± 6.8 | ||||||
| Captopril 0.5 mg/kg | 13.2 ± 1.6 y 12.4 ± 2.9 y 2.7 ± 3.3 y 1.44 ± 1.4 y |
12 12 12 12 |
RHDF: 28.33 ± 5.78 RHD: 26.5 ± 4.91 CHD: 28.5 ± 6.6 DCM: 29.25 ± 4.52 |
RHDF: 15.3 ± 5.3* RHD: 10.7 ± 2.5* CHD: 11.5 ± 3.8* DCM: 15.7 ± 10.7* |
mean ± SD | Serum | III | Kotby et al. (17) | |
| None | 7.8 ± 5 | 12 | 5.54 ± 1.41 | ||||||
ANP, Atrial/A-type Natriuretic Peptide; AO, aorta; ASD, atrial septal defect; CHD, congenital heart disease; d, days; DCM, dilated cardiomyopathy; FU, follow-up after 7-30 days; h, hours; IVC, inferior vena cava; LA, left atrium; LRS, left-to-tight shunt; min, minutes; mo, months; n, number; n/a, not available; PA, pulmonary artery; PBF, pulmonary blood flow; RA, right atrium; RHD, rheumatic heart disease; RHDF, rheumatic heart disease in failure; SD, standard deviation; TOF, tetralogy of Fallot; y, years.
statistically significant decrease through intervention,
n.s. non-significant.
Sample collection protocol:
I = detailed information available regarding: blood sampling procedure, used inhibitors, storage conditions.
III = without any information regarding: blood sampling procedure, used inhibitors, storage conditions.